itch in psoriasis CD26/DPPIV,
Conditions
Interventions
• Patient aged ≥ 18 years old.
• Moderate to severe plaque-
type psoriasis (Psoriasis Area and Severity Index
PASI >10) patient.
Basic Science
psoriasis
Sponsors
The National Research Council of Thailand
Thammasart university
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria • Patient aged ≥ 18 years old. • Moderate to severe plaque-type psoriasis (Psoriasis Area and Severity Index; PASI >10) patient with pruritus.
Exclusion criteria
Exclusion criteria: Exclusion criteria • Patients’ refusal to give a consent • Patient taking other treatment for the disease; topical therapies within 2 weeks, systemic therapies and phototherapy within 4 weeks prior the study period. • Patient with contraindication of narrowband UVB (e.g. xeroderma pigmentosum, other inherited disorder associated with UV-induced carcinogenesis, photodermatosis, history of skin cancer) • Patient with known history of photosensitivity • Presence of psoriasis arthritis • Patient with CD26 and DPPIV associated diseases -T-cell leukemia/lymphoma, as Mycosis fungoides (MF) and Sezary syndrome (SS), Non-Hodgkin's lymphoma, T-cell large granular lymphocyte leukemia, Systemic lupus erythematosus, rheumatoid arthritis, Diabetes mellitus, cancer, chronic diseases, HIV infection , Allergic disease , Atopic dermatitis • Patient with substance P associated diseases and drugs o Chronic urticarial, Prurigo nodularis, Major depressive disorder, anxiety, Uremia, Diabetic mellitus, Chronic pancreatitis, Coronary artery disease, Ulcerative colitis and Crohn's disease, Behçet's disease, Inflammatory bowel disease, Sickle cell crisis, Rheumatological diseases, Infectious diseases (such as AIDS and respiratory syncytial virus), Cancer, Autoimmune myelofibrosis, Liver diseases and Cirrhosis o Nicergoline, Chemotherapy, Hormone therapy, Etanercept, Anti-histamine, Tropisetron • presence of autoimmune disease or immunocompromised conditions • unreliable and poor compliance patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum levels of DPPIV/CD26 and truncated SP the laboratory process launch in one day, after no more than 1 month of serum storage ELISA KITs | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI score before and after irradiation PASI score,visaul analog scale (VAS) score and itch severity scale (ISS) before and after irradiation visaul analog scale (VAS) score and itch severity scale (ISS) ,The Dermatology life Quality Index (DLQI) before and after irradiation The Dermatology life Quality Index (DLQI) | — |
Countries
Thailand
Contacts
Public Contactsupicha kongthong
dermatology
Outcome results
None listed